| Published May 23, 2025

A visionary outlook on cancer therapy for 2040

This panel on the future of immunooncology has a star-striking lineup with Mikael Dolsten, former President of R&D at Pfizer and now senior advisor to eg equity giant Blackstone; world...

Create account to read this article for free

Get free access to a limited number of articles.